| Species | Original | Mutated to | Mutation |
| Human | Trp 85 |
|
|
| Rat Equivalent | Trp 90 | ||
| Mouse Equivalent | Trp 90 |
Cells with W90A receptors did not produce whole cell currents with high concentrations of 5-HT concentrations nor was there detectable specific binding of the antagonist [3H]granisetron.
Twenty six residues (I71, Y73,W90, R92, N128, E129, Y143, Y153, T179, T181, S182,W183, L184, W195, V201, R202, S203, S206, I207, F226, I228, D229, I230, Y234, E236, K238) thought to be within 5A of the 5-HT binding site were substituted with either alanine or a residue with somewhat similar physicochemical properties to the wildtype residue. The effects of these substitutions were investigated by measuring the binding of [3H]granisetron. The results were used to map the granisetron binding site within an homology model of the mouse 5-HT3A receptor based on the crystal structure of the AChBP. Mouse 5-HT3A receptors were expressed in HEK293 cells for radioligand binding.
In addition to [3H]granisetron binding, immunofluorescence was used to examine whether non-binding mutant receptors reached the cell surface. This approach demonstrated that W90A, E129A, E129D, W183A, W183Y and Y234A mutant receptors were expressed at the cell membrane even though there was no [3H]granisetron binding. The table below lists those mutations that significantly affected [3H]granisetron binding.
The W90A mutant 5-HT3A receptor does not bind to [3H]granisteron. The wild type receptor bound [3H]granisteron with a Kd = 0.31 +/- 0.04 nM. The W90Y (Kd = 0.90 +/- 0.06 nM) mutant bound [3H]granisetron with a reduced affinity. Tyrosine, like tryptophan contains an aromatic ring which is presumably required for the correct structure of the antagonist binding site.
| Receptor | [3H]granisetron binding (Kd) |
| WT | 0.31+/-0.04 |
| W90A* | NB |
| W90Y* | 0.90 +/- 0.06 |
| R92A* | 1.80 +/- 0.40 |
| R92K | 1.00 +/- 0.30 |
| E129A* | NB |
| E129D* | NB |
| Y153A* | 2.36 +/- 0.53 |
| Y153F | 0.90 +/- 0.20 |
| T179A* | 3.20 +/- 0.10 |
| T179S | 0.38 +/- 0.20 |
| S181A* | 0.12 +/- 0.04 |
| S181S | 0.58 +/- 0.10 |
| S182A* | 1.00 +/- 0.20 |
| S182T* | 1.80 +/- 0.09 |
| W183A*/Y* | NB |
| L184A* | 4.11 +/- 0.94 |
| L184I* | 0.71 +/- 0.05 |
| W195A* | 5.08 +/- 0.88 |
| W195Y* | 8.70 +/- 2.40 |
| S203A* | 0.08 +/-0.02 |
| S203T | 0.26 +/- 0.11 |
| S206A* | 1.67 +/- 0.27 |
| S206T* | 4.40 +/- 0.49 |
| I228A* | 1.40 +/- 0.30 |
| I228N | 0.30 +/- 0.05 |
| D229A* | 3.80 +/- 0.26 |
| D229E* | 0.11 +/- 0.03 |
| I230A | 0.30 +/- 0.10 |
| I230N* | 1.70 +/- 0.40 |
| Y234A* | NB |
| Y234F | 1.30 +/- 0.36 |
NB, No binding
* significantly different from the WT 5-HT3A receptor
| inhibition of curare (10nM) |
binding of [3H] granisetron (Kd) |
Curare Inhibition (Ki) |
MDL 72222 | Serotonin | phenylbiguanide | m-chlorophynylbiguanide | |
| wild-type | 85% | 1.3 +/- 0.1nM | 138 +/- 22nM | ||||
| W90F | 15% | 10.9 +/- 2.9nM | 1063 +/- 179 nM | similar reduction as curare |
no significant difference in affinity |
no significant difference in affinity |
no significant difference in affinity |
Nine residues (Thr 86, Thr 87, Tyr 88, Ile 89, Tyr 91, Arg 92, Gln 93, Tyr 94, Trp 95) were mutated individually to alanine. The ligands [3H]granisetron, curare, and serotonin were used to examine the properites of 5-HT3 receptor binding sites.
W90F was analyzed instead of W90A, and it proved to be the only one that significantly affected the interaction of curare with the receptor. R92A was the only substitution that altered the affinity of the agonist serotonin. W90F, R92A, and Y94A all reduced the affinity of [3H]granisetron. The periodicity of the effect suggests the involvement of a beta-strand.
| Wild-Type | W90Y | |
| [3H] Granisetron (Kd) | 0.17 +/- 0.003 | 0.92 +/- 0.06 |
| [3H] Granisetron (nH) | 1.03 +/- 0.11 | 0.92 +/- 0.03 |
| [3H] mCPBG (Kd) | 1.48 +/- 0.09 | 8.24 +/- 0.73 |
| [3H] mCPBG (nH) | 1.07 +/- 0.02 | 1.00 +/- 0.003 |
| mCPBG (EC50) | 0.81 +/- 0.09 | 2.00 +/- 0.10 |
| mCPBG (nH) | 1.97 +/- 0.20 | 2.14 +/- 0.13 |
| 5-HT3 (EC 50) | 2.10 +/- 0.40 |
8.02 +/- 0.30 |
| 5-HT3 (nH) | 2.22 +/- 0.20 | 2.02 +/- 0.11 |
| 2-Me-5-HT (EC50) | 12.7 +/- 0.45 uM | 12.9 +/- 1.98 uM |
| 2-Me-5-HT (nH) | no significant change |
Twenty six residues (I71, Y73,W90, R92, N128, E129, Y143, Y153, T179, T181, S182,W183, L184, W195, V201, R202, S203, S206, I207, F226, I228, D229, I230, Y234, E236, K238) thought to be within 5A of the 5-HT binding site were substituted with either alanine or a residue with somewhat similar physicochemical properties to the wildtype residue. The effects of these substitutions were investigated by measuring the binding of [3H]granisetron. The results were used to map the granisetron binding site within an homology model of the mouse 5-HT3A receptor based on the crystal structure of the AChBP. Mouse 5-HT3A receptors were expressed in HEK293 cells for radioligand binding.
In addition to [3H]granisetron binding, immunofluorescence was used to examine whether non-binding mutant receptors reached the cell surface. This approach demonstrated that W90A, E129A, E129D, W183A, W183Y and Y234A mutant receptors were expressed at the cell membrane even though there was no [3H]granisetron binding. The table below lists those mutations that significantly affected [3H]granisetron binding.
The W90A mutant 5-HT3A receptor does not bind to [3H]granisteron. The wild type receptor bound [3H]granisteron with a Kd = 0.31 +/- 0.04 nM. The W90Y (Kd = 0.90 +/- 0.06 nM) mutant bound [3H]granisetron with a reduced affinity. Tyrosine, like tryptophan contains an aromatic ring which is presumably required for the correct structure of the antagonist binding site.
| Receptor | [3H]granisetron binding (Kd) |
| WT | 0.31+/-0.04 |
| W90A* | NB |
| W90Y* | 0.90 +/- 0.06 |
| R92A* | 1.80 +/- 0.40 |
| R92K | 1.00 +/- 0.30 |
| E129A* | NB |
| E129D* | NB |
| Y153A* | 2.36 +/- 0.53 |
| Y153F | 0.90 +/- 0.20 |
| T179A* | 3.20 +/- 0.10 |
| T179S | 0.38 +/- 0.20 |
| S181A* | 0.12 +/- 0.04 |
| S181S | 0.58 +/- 0.10 |
| S182A* | 1.00 +/- 0.20 |
| S182T* | 1.80 +/- 0.09 |
| W183A*/Y* | NB |
| L184A* | 4.11 +/- 0.94 |
| L184I* | 0.71 +/- 0.05 |
| W195A* | 5.08 +/- 0.88 |
| W195Y* | 8.70 +/- 2.40 |
| S203A* | 0.08 +/-0.02 |
| S203T | 0.26 +/- 0.11 |
| S206A* | 1.67 +/- 0.27 |
| S206T* | 4.40 +/- 0.49 |
| I228A* | 1.40 +/- 0.30 |
| I228N | 0.30 +/- 0.05 |
| D229A* | 3.80 +/- 0.26 |
| D229E* | 0.11 +/- 0.03 |
| I230A | 0.30 +/- 0.10 |
| I230N* | 1.70 +/- 0.40 |
| Y234A* | NB |
| Y234F | 1.30 +/- 0.36 |
NB, No binding
* significantly different from the WT 5-HT3A receptor
The mutation of W90S did not show any response to [3H] Granisetron, [3H] mCPBG, 5-HT or mCPBG.